Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem C...
Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
About this item
Full title
Author / Creator
Publisher
Chicago, IL: The University of Chicago Press
Journal title
Language
English
Formats
Publication information
Publisher
Chicago, IL: The University of Chicago Press
Subjects
More information
Scope and Contents
Contents
Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the ov...
Alternative Titles
Full title
Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_68291559
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_68291559
Other Identifiers
ISSN
1058-4838
E-ISSN
1537-6591
DOI
10.1086/521912
